Full Breakdown
EU Secures Emergency Favipiravir Doses for Hantavirus Outbreak
5/28/2026, 11:51:37 PM
Emergency Dispatch of Favipiravir to France, Spain, and the Netherlands
On 28 May 2026 the European Commission announced that the first doses of an experimental antiviral for hantavirus treatment are being dispatched to France, Spain and the Netherlands. The shipment follows a donation of 1,400 tablets of favipiravir from Fujifilm Pharmaceuticals in Japan, which the three Member States had requested. The EU has simultaneously launched emergency procurement procedures to obtain additional doses should further cases emerge in the coming weeks.
Outbreak Background and Health Context
The current outbreak is linked to a cruise ship and has resulted in 13 confirmed hantavirus infections across Europe and beyond. Patients are receiving care in the Netherlands, France, Spain, Switzerland, the United States and South Africa. Hantaviruses are rodent-borne pathogens; the World Health Organization estimates up to 100 000 human cases globally each year. While the virus can be deadly, severity varies by strain and human-to-human transmission is rare. Since the start of this outbreak, three deaths have been reported.
Key Actors and International Partnerships
- European Commission – coordinated the emergency dispatch and procurement.
- European Medicines Agency (EMA) – identified favipiravir as the most plausible candidate for clinical-trial or compassionate-use protocols.
- Fujifilm Pharmaceuticals (Japan) – supplied the initial 1,400 tablets.
- Commissioner Mohamed Lahbib – highlighted EU-Japan cooperation in securing the treatment.
- Japanese authorities and the EU Delegation to Japan – facilitated the donation under the EU-Japan health-emergency partnership.
Data and Statistics
- Confirmed cases: 13 (linked to the cruise ship).
- Reported deaths: 3.
- Favipiravir tablets donated: 1,400.
- WHO global hantavirus estimate: ? 100,000 cases per year.
Official Statements and Responses
The Commission’s statement emphasized rapid access to a potential medical countermeasure, noting that the EMA’s assessment positioned favipiravir as the leading candidate for experimental use. Commissioner Lahbib underscored the role of solidarity and preparedness, stating that close cooperation between the EU, its Member States, and Japanese partners enabled swift action to protect European patients. The EU’s emergency procurement plan aims to expand the stockpile pending further epidemiological assessment.
Verbatim Quotes
- “The first doses of an experimental antiviral for hantavirus treatment are being dispatched to France, Spain and the Netherlands, the European Commission said on May 28.” — European Commission
- “In the absence of a specific treatment for hantavirus, the European Medicines Agency identified favipiravir as the most plausible candidate for use under clinical trial or compassionate use protocols, the commission said in a statement.” — European Commission (statement)
- “Fujifilm Pharmaceuticals in Japan donated 1,400 tablets of favipiravir, which France, Spain and the Netherlands had requested.” — European Commission (statement)
- “Solidarity and rapid action save lives. Thanks to close cooperation between the EU, Member States and our Japanese partners, we were able to rapidly secure access to potentially life-saving Hantavirus treatments for European patients. This shows the value of preparedness, cooperation and trusted global partnerships” — Mohamed Lahbib, EU Commissioner for Crisis Management
What’s Next
The EU’s emergency procurement will continue while health authorities monitor the outbreak’s trajectory. Additional favipiravir doses may be secured for clinical trials or compassionate use, and the Commission will maintain coordination with member states and international partners to ensure rapid response to any further hantavirus cases.
